Research Overview
Selank is a synthetic heptapeptide analog of the immunomodulator tuftsin, with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The C-terminal Pro-Gly-Pro extension confers resistance to proteolytic degradation, allowing the molecule to persist in plasma and central tissue compartments longer than native tuftsin.
The product is supplied as a lyophilized powder, 10mg per vial, sequence TKPRPGP, molecular weight 751.86 g/mol, CAS 129954-34-3, with HPLC-verified purity of 99.0%. Selank was developed at the Institute of Molecular Genetics, Russian Academy of Sciences, and has been investigated extensively in Russian-language neuropharmacology research and in English-language peer-reviewed work.
The compound is intended strictly for in vitro laboratory research and is not for human or veterinary use. Within the nootropic peptide category, Selank has been investigated specifically in anxiolytic-class behavioral models, GABA-A receptor pharmacology research, BDNF expression studies, and inflammatory cytokine modulation research.
Researchers studying short-chain neuropeptide tool compounds frequently procure Selank alongside SEMAX, with both peptides forming a complementary pair in Russian-origin neuropeptide research panels. Documentation including Certificate of Analysis, HPLC purity trace, and mass spectrometry confirmation is available on request to verified research accounts.
Mechanism Studied in Research
Selank has been investigated as a multi-target neuropeptide with pharmacology centered on GABAergic, monoaminergic, and neurotrophic systems.
Mechanistic studies have examined modulation of GABA-A receptor subunit expression, effects on neurotransmitter release, and regulation of neurotrophic factors including BDNF. Research has also investigated cytokine-signaling pathways and immunomodulatory mechanisms associated with Selank administration in experimental models.
Additional work has examined peptide stability, receptor interactions, and behavioral outcomes linked to anxiety-related neurobiological pathways.
Research Applications
Selank has been investigated across multiple research domains relevant to neuropharmacology, behavioral neuroscience, and immunology.
Research protocols have evaluated Selank in anxiety-related behavioral models, learning and memory studies, stress-response investigations, and neurotransmitter-system research.
Studies have also examined inflammatory cytokine expression, BDNF signaling, GABAergic mechanisms, and neuroprotective pathways. Researchers frequently investigate Selank alongside SEMAX as part of broader neuropeptide research programs.
The compound continues to be studied in experimental models exploring neuroimmune communication, stress adaptation, and behavioral regulation.
Reconstitution Reference
Selank is supplied as a lyophilized powder, 10mg per vial. Reconstitution is commonly performed using bacteriostatic water.
Researchers frequently add 2mL of diluent to produce a 5mg per mL stock solution. The diluent should be introduced slowly along the inner wall of the vial to minimize foaming and peptide stress.
The vial should be gently swirled until dissolved. Vigorous shaking should be avoided. Following reconstitution, researchers should label the vial with the reconstitution date, diluent type, concentration, and batch number for laboratory documentation.
Storage and Handling
Lyophilized Selank should be stored at -20°C when protected from light and moisture.
Once reconstituted, the solution should be refrigerated at 2-8°C and used according to validated laboratory protocols. Repeated freeze-thaw cycles should be avoided.
Storage conditions, reconstitution dates, and handling procedures should be documented to maintain laboratory traceability and chain-of-custody records.
References
[2] ... PMID 20478142
[3] ... PMID 18184302
[4] ... PMID 18277482